Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

ASX utility share downgraded as electricity prices fall

Falling electricity prices weigh on earnings outlook for utility provider.
stocks

Chart of the Week: AI market leader is now surprisingly cheap

This AI beneficiary may still be one of the market’s most compelling bargains.
stocks

Weekly earnings wrap: Rio Tinto leads the way

A closer look at the key earnings results from the first week of August reporting.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,452.0042.100.45%
CAC 408,727.9058.610.68%
DAX 4026,137.4311.130.04%
Dow JONES (US)54,349.12263.240.49%
FTSE 10010,905.7417.440.16%
HKSE25,530.28385.54-1.49%
NASDAQ26,363.44221.55-0.83%
Nikkei 22565,683.26617.18-0.93%
NZX 50 Index13,958.0639.12-0.28%
S&P 5007,723.550.000.00%
S&P/ASX 2009,271.6041.800.45%
SSE Composite Index3,900.3521.920.57%

Market Movers